Skip to main content
Erschienen in: Rheumatology International 8/2012

01.08.2012 | Original Article

Serum levels of macrophage migration inhibitory factor are associated with rheumatoid arthritis course

verfasst von: Mara Anaís Llamas-Covarrubias, Yeminia Valle, Rosa Elena Navarro-Hernández, Iris Paola Guzmán-Guzmán, María Guadalupe Ramírez-Dueñas, Héctor Rangel-Villalobos, Ciro Estrada-Chávez, José Francisco Muñoz-Valle

Erschienen in: Rheumatology International | Ausgabe 8/2012

Einloggen, um Zugang zu erhalten

Abstract

Rheumatoid arthritis (RA) is an inflammatory autoimmune disease of unknown etiology. Many cytokines have been found to be associated with RA pathogenesis and among them is macrophage migration inhibitory factor (MIF). The aim of this study was to determine whether MIF serum levels are associated with RA course, clinical activity, and clinical biomarkers of the disease. MIF levels were determined in serum samples of 54 RA patients and 78 healthy subjects (HS) by enzyme-linked immunosorbent assay (ELISA). Disease activity was evaluated using the DAS28 score. Patients were subgrouped according to disease activity and years of evolution of disease. Statistical analysis was carried out by SPSS 10.0 and GraphPad Prism 5 software. RA patients presented increased levels of MIF as compared to HS. MIF levels were raised on early stages of RA and tend to decrease according to years of evolution. Moreover, MIF levels positively correlated with rheumatoid factor in RA patients and with C reactive protein in all individuals studied. Our findings suggest that MIF plays a role in early stages of RA.
Literatur
1.
Zurück zum Zitat McInnes IB, Schett G (2007) Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7:429–442PubMedCrossRef McInnes IB, Schett G (2007) Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7:429–442PubMedCrossRef
2.
Zurück zum Zitat David JR (1966) Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA 56:72–77PubMedCrossRef David JR (1966) Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA 56:72–77PubMedCrossRef
3.
Zurück zum Zitat Calandra T, Roger T (2003) Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 3:791–800PubMedCrossRef Calandra T, Roger T (2003) Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 3:791–800PubMedCrossRef
4.
Zurück zum Zitat Denkinger CM, Metz C, Fingerle-Rowson G et al (2004) Macrophage migration inhibitory factor and its role in autoimmune diseases. Arch Immunol Ther Exp 52:389–400 Denkinger CM, Metz C, Fingerle-Rowson G et al (2004) Macrophage migration inhibitory factor and its role in autoimmune diseases. Arch Immunol Ther Exp 52:389–400
5.
Zurück zum Zitat Willeke P, Gaubitz M, Schotte H et al (2007) Increased serum levels of macrophage migration inhibitory factor in patients with primary Sjögren′s syndrome. Arthritis Res Ther 9:R43PubMedCrossRef Willeke P, Gaubitz M, Schotte H et al (2007) Increased serum levels of macrophage migration inhibitory factor in patients with primary Sjögren′s syndrome. Arthritis Res Ther 9:R43PubMedCrossRef
7.
Zurück zum Zitat Leech M, Metz C, Hall P et al (1999) Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflamatory function and regulation by glucocorticoids. Arthritis Rheum 42:1601–1608PubMedCrossRef Leech M, Metz C, Hall P et al (1999) Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflamatory function and regulation by glucocorticoids. Arthritis Rheum 42:1601–1608PubMedCrossRef
8.
Zurück zum Zitat Prevoo MLL, Van’T Hof MA, Kuper HH et al (1995) Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48PubMedCrossRef Prevoo MLL, Van’T Hof MA, Kuper HH et al (1995) Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48PubMedCrossRef
9.
Zurück zum Zitat Weinblatt ME, Kremer JM, Bankhurst AD et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253–259PubMedCrossRef Weinblatt ME, Kremer JM, Bankhurst AD et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253–259PubMedCrossRef
10.
Zurück zum Zitat Thaler K, Chandiramani DV, Hansen RA et al (2009) Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project. Biologics 3:485–498PubMed Thaler K, Chandiramani DV, Hansen RA et al (2009) Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project. Biologics 3:485–498PubMed
11.
Zurück zum Zitat Nishimoto N, Miyasaka N, Yamamoto K et al (2009) Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 68:1580–1584PubMedCrossRef Nishimoto N, Miyasaka N, Yamamoto K et al (2009) Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 68:1580–1584PubMedCrossRef
12.
Zurück zum Zitat Leech M, Metz C, Santos L, Peng et al (1998) Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis. Arthritis Rheum 41:910–917PubMedCrossRef Leech M, Metz C, Santos L, Peng et al (1998) Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis. Arthritis Rheum 41:910–917PubMedCrossRef
13.
Zurück zum Zitat Onodera S, Ohshima S, Tohyama H et al (2007) A novel DNA vaccine targeting macrophage migration inhibitory factor protects joints from inflammation and destruction in murine models of arthritis. Arthritis Rheum 56:521–530PubMedCrossRef Onodera S, Ohshima S, Tohyama H et al (2007) A novel DNA vaccine targeting macrophage migration inhibitory factor protects joints from inflammation and destruction in murine models of arthritis. Arthritis Rheum 56:521–530PubMedCrossRef
14.
Zurück zum Zitat Leech M, Metz C, Bucala R et al (2000) Regulation of macrophage migration inhibitory factor by endogenous glucocorticoids in rat adjuvant-induced arthritis. Arthritis Rheum 43:827–833PubMedCrossRef Leech M, Metz C, Bucala R et al (2000) Regulation of macrophage migration inhibitory factor by endogenous glucocorticoids in rat adjuvant-induced arthritis. Arthritis Rheum 43:827–833PubMedCrossRef
15.
Zurück zum Zitat Martinez A, Orozco G, Varadé J et al (2007) Macrophage migration inhibitory factor gene: influence on rheumatoid arthritis susceptibility. Hum Immunol 68:744–747PubMedCrossRef Martinez A, Orozco G, Varadé J et al (2007) Macrophage migration inhibitory factor gene: influence on rheumatoid arthritis susceptibility. Hum Immunol 68:744–747PubMedCrossRef
16.
Zurück zum Zitat Radstake TR, Sweep FC, Welsing P et al (2005) Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum 52:3020–3029PubMedCrossRef Radstake TR, Sweep FC, Welsing P et al (2005) Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum 52:3020–3029PubMedCrossRef
17.
Zurück zum Zitat Wheelhouse NM, Dowidar N, Dejong CHC et al (2006) The effects of macrophage migratory inhibitory factor on acute-phase protein production in primary human hepatocytes. Int J Mol Med 18:957–961PubMed Wheelhouse NM, Dowidar N, Dejong CHC et al (2006) The effects of macrophage migratory inhibitory factor on acute-phase protein production in primary human hepatocytes. Int J Mol Med 18:957–961PubMed
18.
Zurück zum Zitat Morand EF, Leech M, Weedon H et al (2002) Macrophage migration inhibitory factor in rheumatoid arthritis: clinical correlations. Rheumatology (Oxford) 41:558–562CrossRef Morand EF, Leech M, Weedon H et al (2002) Macrophage migration inhibitory factor in rheumatoid arthritis: clinical correlations. Rheumatology (Oxford) 41:558–562CrossRef
19.
Zurück zum Zitat Bacher M, Metz CN, Calandra T, Mayer et al (1996) An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 93:7849–7854PubMedCrossRef Bacher M, Metz CN, Calandra T, Mayer et al (1996) An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 93:7849–7854PubMedCrossRef
Metadaten
Titel
Serum levels of macrophage migration inhibitory factor are associated with rheumatoid arthritis course
verfasst von
Mara Anaís Llamas-Covarrubias
Yeminia Valle
Rosa Elena Navarro-Hernández
Iris Paola Guzmán-Guzmán
María Guadalupe Ramírez-Dueñas
Héctor Rangel-Villalobos
Ciro Estrada-Chávez
José Francisco Muñoz-Valle
Publikationsdatum
01.08.2012
Verlag
Springer-Verlag
Erschienen in
Rheumatology International / Ausgabe 8/2012
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-011-1951-6

Weitere Artikel der Ausgabe 8/2012

Rheumatology International 8/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.